Contract Consulting & Pharmaceutical Services - Part 1

Published on: 
BioPharm International, BioPharm International-09-02-2009, Volume 2009 Supplement, Issue 5

To assess current trends in outsourcing, BioPharm International turned to Mark Douglas, PhD, strategic business development manager, Avecia Biologics Ltd; Geoffrey M. Glass, senior vice president of strategy, corporate development and business integration, Patheon Inc.; Rob Gustines, director of marketing, KBI Biopharma, Inc.; Jon S. Kauffman, PhD, director, method development & method validation and biopharmaceutical services, Lancaster Laboratories; Roger Lias, PhD, president, Eden Biodesign, Inc.; John A. McCarty, vice president, formulation sciences and drug delivery, Azopharma; and Michiel E. Ultee, PhD, vice president, process sciences, Laureate Pharma, Inc.

Related Content:

OutsourcingBioBusinessBioPharm International-09-02-2009
Novo Nordisk to Make Multi-Billion Dollar Investment in Expansion of Production Facilities in France
New Medicines, Markets, and Manufacture: CRISPR for Sickle Cell Disease and β-thalassemia
Genentech and NVIDIA Form AI Research Collaboration for Drug Discovery and Development